Actinium-225 PSMA therapy is an emerging treatment for advanced prostate cancer that focuses on delivering targeted radiation ...

Actimab-A, Actinium's lead radiotherapeutic, delivers Actinium-225, a potent alpha-emitter radioisotope designed to induce lethal DNA damage in targeted cells. It has been studied in over 150 ...

Prostate cancer poses significant challenges for many patients. Radioligand therapies have offered hope by targeting cancer cells with precision. While Lutetium-177 therapy has been effective for many ...

纽约 - 根据InvestingPro数据显示，过去一周股价上涨近10%的Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM)报告了一项临床试验的积极结果。该试验研究了Actimab-A与CLAG-M化疗联合用于复发或难治性急性髓系白血病 (r/r ...

Actinium Pharmaceuticals (ATNM) announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M ...

Actimab-A is Actinium's lead radiotherapeutic that delivers Actinium-225, a potent alpha-emitter radioisotope payload that can produce lethal double strand DNA breaks to kill targeted cells.

The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it will participate at the 37th Annual Roth ...

Actinium Pharmaceuticals (ATNM) announced that the first clinical trial under its previously announced Cooperative Research and Development ...

- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA ® or OPDIVO ® can result in improved patient outcomes - MDSCs – Myeloid Derived Suppressor Cells in ...

Actinium holds 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. This press release may contain projections or other ...